Zdrowie i gospodarka · 12/03/2019
FDA Requests Public Comment on Proposed Collection of Information for Biosimilars User Fee Act Reviews
The Food and Drug Administration is seeking public input on its proposed collection of information for reviewing 351(k) biologics license applications under the Biosimilars User Fee Act, with a 60-day comment period set to end in March 2024.